ankylosing spondylitis

Fenbufen (Lederfen) is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures. Fenbufen is available as a capsule or tablet sold with the brand names Cepal, Cinopal, Cybufen, Lederfen, and Reugast. Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation.

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

Aceclofenac (Preservex) is a non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties.

Phenylbutazone (Butazolidine) is a butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ankylosing spondylitis, rheumatoid arthritis, and reactive arthritis.

SGC-CBP30 is an effective CREBBP EP300 inhibitor (IC50: 21 38 nM).

Salazosulfamide has shown potential in the treatment of ankylosing spondylitis, according to research studies.

Azapropazone is anti-inflammatory agent. Azapropazone has uricosuric properties used to treat rheumatoid arthritis and ankylosing spondylitis. Azapropazone lowered plasma uric acid but exerted only a modest and variable uricosuric effect without altering

IL-17 Modulator 1 (disodium) is a potent, orally active compound, known for its high efficacy in modulating IL-17. This compound is extensively utilized for researching various diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis[1].

(R)-Elsubrutinib ((R)-ABBV-105), a Btk inhibitor, is utilized in research on immune disorders [including rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus] and cancer.

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].

Gumokimab (AK 111) is a humanized monoclonal antibody designed to specifically target interleukin-17A (IL-17A). it functions by competitively inhibiting the binding of IL-17A to its cognate receptor, thereby blocking downstream pro-inflammatory signaling, Gumokimab is a candidate for therapeutic research in psoriasis and ankylosing spondylitis.